Related Experiment Video
Updated: Nov 28, 2025
Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance
Misti Ellsworth1, Luis Ostrosky-Zeichner2
1Division of Pediatric Infectious Diseases, UT Health McGovern Medical School, Houston, TX 77030, USA.
Abstract:
Increasing incidence of invasive fungal infections combined with a growing population of immunocompromised hosts has created a rising need for antifungal agents. Isavuconazole, a second-generation broad-spectrum triazole with activity against yeasts, dimorphic fungi, and molds, has a favorable safety profile and predictable pharmacokinetics. Patients typically tolerate isavuconazole well with fewer drug-drug interactions. Clinical trials have found it to be noninferior to voriconazole for invasive aspergillosis, an alternative therapy for salvage treatment of mucormycosis, and suitable for stepdown therapy with invasive candidiasis. Cross-resistance with other triazoles is common. More studies are needed to determine the role of isavuconazole in anti-mold prophylaxis in high-risk patients.
Insights
Isavuconazole is a new antifungal drug effective against various fungi, with a good safety profile. It shows promise for treating invasive fungal infections in immunocompromised patients.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Rising incidence of invasive fungal infections (IFIs) necessitates novel antifungal agents.
- Growing population of immunocompromised hosts increases susceptibility to IFIs.
- Need for antifungals with favorable safety and predictable pharmacokinetics.
Purpose of the Study:
- To review the role of isavuconazole, a second-generation triazole, in treating IFIs.
- To evaluate its efficacy, safety, and pharmacokinetic profile.
- To compare its utility against existing antifungal therapies.
Main Methods:
- Review of clinical trials and existing literature on isavuconazole.
- Analysis of its activity against yeasts, dimorphic fungi, and molds.
- Assessment of safety profile and drug-drug interactions.
Main Results:
- Isavuconazole demonstrates broad-spectrum activity against various fungi.
- It is noninferior to voriconazole for invasive aspergillosis.
- It serves as an alternative for mucormycosis salvage and stepdown for invasive candidiasis.
- Generally well-tolerated with fewer drug-drug interactions.
Conclusions:
- Isavuconazole is a valuable addition to the antifungal armamentarium.
- Its predictable pharmacokinetics and safety profile are advantageous.
- Further research is needed to define its role in prophylaxis for high-risk patients.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
01:28Antimicrobial Effectiveness
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:30Development of Antibiotic Resistance
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:21Factors Affecting Drug Response: Overview
01:21Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...